| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $4.25 | - | - |
| Q1'26 | $4.29 | $2.63 | -38.7% |
| Q4'25 | $2.90 | $2.86 | -1.2% |
| Q3'25 | $3.78 | $3.88 | +2.7% |
| Q2'25 | $3.79 | $3.88 | +2.3% |
| Q1'25 | $2.20 | $2.45 | +11.3% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $6.4B | - | - |
| Q1'26 | $6.2B | $5.0B | -19.3% |
| Q4'25 | $5.2B | $5.1B | -1.8% |
| Q3'25 | - | $5.7B | - |
| Q2'25 | - | $5.7B | - |
| Q1'25 | - | $4.7B | - |
Market Data
TT is currently trading at $480.00, giving Trane Technologies plc a market cap of 106.39B and a P/E ratio of 36.7. Today's range spans $469.82–$482.51, with shares opening at $472.00 and moving up $0.23 (0.0%) from the prior close. DailyIQ's technical score sits at 77/100 (BUY) with a news sentiment reading of 70/100.
Over the past year TT has traded between $348.06 and $505.87 - the current price is +37.9% off the 52-week low and -5.1% from the high. 35 analysts cover the stock with a Hold consensus and a mean 12-month target of $522.61 (range $402.00–$570.00), implying upside of +8.9%.
The bullish case for TT is built on complementary signals: 77/100 technical score, BUY designation, and bullish sentiment at 70/100. At $480.00 (in the upper portion of its 52-week range within $348.06–$505.87), the stock is at a capitalization - 106.39B - where active managers can build meaningful positions without moving the market. (P/E: 36.7) That combination of signal quality and position-buildability makes this one of the more actionable large-cap setups in Industrials.
What makes TT's BUY setup (77/100) particularly actionable at 106.39B in Industrials capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $480.00 (in the upper portion of its 52-week range in $348.06–$505.87), with sentiment running bullish at 70/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).